Ocular's lead product fails in second PhIII
This article was originally published in Scrip
Ocular Therapeutix's sank on 7 April following mediocre results from a second Phase III trial of the company's lead product candidate, OTX-DP (sustained release dexamethasone).
You may also be interested in...
Regeneron is partnering with the troubled ophthalmology-focused biotech to develop a sustained-release formulation of Eylea that could enable a less-frequent dosing regimen.
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.
Emerging Company Profile: Irish start-up Shorla Pharma recently secured $8.3m to move its pipeline candidates into the clinic. While it is not the largest series A financing for an emerging biotech, the company expects to get its first “re-innovated” product approved in the US next year.